MSD sues Pfizer’s Wyeth over vaccine patents
Pharmaceutical company MSD has urged a federal court to rule that its new vaccine doesn’t infringe three patents owned by Pfizer’s subsidiary, Wyeth, because they are invalid.
EPA and OSHA to share secrets on workplace chemical exposure
Two federal agencies in the US have agreed to share confidential business information about the manufacture of chemicals that are produced and imported, in efforts to improve the protection of workers who may be exposed to a new chemical substance.
Illumina accused of fraud in DNA tech patents dispute
Illumina tried to secure its control over the DNA sequencing technology market by violating antitrust law, according to a suit by BGI Americas and two of its subsidiaries, at the US Court for the District Court of San Francisco.
Sanofi buys Kymab in boost to immunotherapy portfolio
Sanofi will buy British immunotherapy firm Kymab for up to $1.45 billion, as it seeks to expand in the rapidly growing immunotherapy field.
SCOTUS weighs future of assignor estoppel
The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.
Roche urges SCOTUS to cancel Illumina patent win
Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.
Generics petition Supreme Court to save PTAB patent trials
Generic drug makers are trying to persuade the US Supreme Court to retain an administrative process for challenging patents, in the latest bid to discredit the controversial decision handed down in Arthrex v Smith & Nephew.
EPA grants chemical makers another chance to protect trade secrets
Chemical manufacturers have a renewed opportunity to protect the confidentiality of the chemicals they make or import, according to an announcement by the US Environmental Protection Agency.
MHRA unveils ‘innovation passport’ for new medicines
A licensing pathway that will reduce the time it takes for novel medicines to enter the marketplace has been launched by the UK Medicines and Healthcare products Regulatory Agency.
MSD and Glenmark appeal pay-for-delay Zetia dispute
Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.
